Rallybio (RLYB) Common Equity (2020 - 2026)
Rallybio (RLYB) posted Common Equity of $50.3 million for Q1 2026, down 13.25% sequentially from $58.0 million in Q4 2025, and down 7.02% YoY from $54.1 million in Q1 2025.
Rallybio (RLYB) Common Equity (2020 - 2026) Analysis & Trends
Rallybio has reported Common Equity for 7 years, with the latest figure at $50.3 million in Q1 2026.
- Quarterly Common Equity fell 7.02% year-over-year to $50.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $50.3 million (down 7.02% YoY) and the FY2025 annual result came in at $58.0 million, down 6.0% from the prior year.
- Common Equity retreated to $50.3 million in Q1 2026 per RLYB's latest filing, from $58.0 million in the prior quarter.
- Over five years, Common Equity peaked at $169.3 million in Q4 2022 and troughed at $46.0 million in Q2 2025.
- A 5-year average of $100.5 million and a median of $89.2 million in 2024 frame the typical range for Common Equity.
- The sharpest annual moves came in 2022 and 2024: Common Equity jumped 32.28% in 2022, then plunged 42.7% in 2024.
- Over 5 years, Common Equity stood at $169.3 million in 2022, then plunged by 37.29% to $106.2 million in 2023, then plunged by 41.94% to $61.7 million in 2024, then fell by 6.0% to $58.0 million in 2025, then retreated by 13.25% to $50.3 million in 2026.
- According to Business Quant data, Common Equity over the past three periods registered $50.3 million, $58.0 million, and $63.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.81 Bn | 131.96 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 86.33 Bn | 78.34 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 65.13 Bn | 59.95 Bn | 1.37 Bn | - |
| 4 | Moderna | 60.47 Bn | 55.33 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 42.10 Bn | 37.00 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 31.04 Bn | 27.73 Bn | 992.69 Mn | 1.35 Bn |
| 7 | BioNTech SE | 28.48 Bn | 10.09 Bn | 668.28 Mn | 22.38 Bn |
| 8 | Insmed | 27.36 Bn | 26.20 Bn | 358.27 Mn | 757.49 Mn |
| 9 | Royalty Pharma | 27.23 Bn | 26.39 Bn | - | 9.79 Bn |
| 10 | Rallybio | 94.78 Mn | 94.78 Mn | - | 94.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 94.50 Mn |
| Mar 31, 2026 | 50.28 Mn |
| Dec 31, 2025 | 57.96 Mn |
| Sep 30, 2025 | 63.03 Mn |
| Jun 30, 2025 | 45.96 Mn |
| Mar 31, 2025 | 54.07 Mn |
| Dec 31, 2024 | 61.65 Mn |
| Sep 30, 2024 | 70.82 Mn |
| Jun 30, 2024 | 80.02 Mn |
| Mar 31, 2024 | 89.16 Mn |
| Dec 31, 2023 | 106.18 Mn |
| Sep 30, 2023 | 123.58 Mn |
| Jun 30, 2023 | 139.26 Mn |
| Mar 31, 2023 | 155.20 Mn |
| Dec 31, 2022 | 169.32 Mn |
| Sep 30, 2022 | 131.94 Mn |
| Jun 30, 2022 | 147.85 Mn |
| Mar 31, 2022 | 163.04 Mn |
| Dec 31, 2021 | 175.60 Mn |
| Sep 30, 2021 | 186.49 Mn |